- Price
- $390.02
- Day
- +2.94%
- Mkt Cap
- $210.50B
- 52W Range
- $269.77 – $398.00
- Volume
- 3.46M
- Beta
- 0.41
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Total Revenues: Exceeded $10 billion, a 10% year-over-year increase.Product Sales Growth: 22 products delivered double-digit sales growth; 17 products annualize
Read full article
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read full article
Amgen NASDAQ: AMGN reported second-quarter revenue above $10 billion, up 10% from a year earlier, as growth across several key medicines offset competitive pressure on its bone-health franchise. The company raised its full-year revenue and adjusted earnings outlook while continuing to increase spending on late-stage clinical programs and manufacturing capacity.
Read full article
Amgen Inc (AMGN) released its 8-K filing on August 4, 2026, detailing its financial results for the second quarter of 2026. The biotechnology giant reported a 1
Read full article
Amgen on Tuesday reported second-quarter sales rose 9%, driven by demand for cholesterol drug Repatha, bone drug Evenity and medications for rare diseases, as the company continues to develop experimental weight-loss drug MariTide.
Read full article
THOUSAND OAKS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from the Amgen data breach.
Read full article
The biotechnology company now expects full-year revenue between $38.2 billion and $39.4 billion, but said it was halting the development of a potential obesity treatment currently in a phase 1 study.
Read full article
THOUSAND OAKS, Calif., Aug. 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2026.
Read full article
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Amgen (AMGN). But which of these two stocks is more attractive to value investors?
Read full article
Amgen Inc. (AMGN) Q2 2026 Earnings Call Transcript
Read full article
Amgen (AMGN) came out with quarterly earnings of $6.29 per share, beating the Zacks Consensus Estimate of $5.6 per share. This compares to earnings of $6.02 per share a year ago.
Read full article
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Read full article